Sun Pharmaceutical Industries

Persistence pays off for Kala

The company’s Eysuvis looks set to be approved for dry eye disease, but meeting expectations in this tough market will not be easy.

Private equity cleans up Sanofi’s failed generics foray

March 23, 2018

Snippet roundup: Funding boosts the US NIH and could spawn a UK ubercorn

February 15, 2018

Vantage view – Doing what's possible on drug prices

January 25, 2018

Interview – Hospital chains seek pricing control

January 04, 2018

What price controls? US FDA keeps focus on generic competition

October 27, 2017

Psoriasis gets more crowded as risankizumab scores

March 09, 2017

Event – FDA panel to re-examine Opana ER

March 09, 2017

Event – FDA panel to re-examine Opana ER

November 16, 2016

Generic pricing pressure could fuel the urge to merge

September 13, 2016

Teva’s transformation reveals a generics market in turmoil

Load More